A type of immunotherapy called a checkpoint inhibitor that blocks the PD-1 protein receptor on cancer cells. Checkpoint inhibitors release the ‘brakes’ on the immune system enabling T cells to kill cancer cells more effectively. Tecentriq is used to treat advanced kidney cancer. Tecentriq is the brand (or trade) name under which the drug is licensed and sold, while atezolizumab is the chemical (or generic) name of the drug.

Share this Post!